Preclinical studies have shown that the combination of PI3K inhibitors with PD-1/PD-L1 inhibitors significantly extends the survival of tumor-bearing mice, suggesting that this strategy may overcome resistance to immunotherapy (90). This evidence concerns the gene CD274 and neoplasm.